PCI Evolution in Infiltrative Diseases

Infiltrative diseases (ID) consist of a heterogeneous series of genetic conditions that cause infiltration and extracellular deposits which alter the diverse systems and organs affected.   

ATC en enfermedades infiltrativas

Amyloidosis, sarcoidosis and hemochromatosis affect the heart, altering the myocardium and the conduction system. 

PCI is often used at present to treat heart disease, and some of these patients present ID. Different analysis suggest that PCI might evolve differently vs. patients with no ID; however, it has not yet been thoroughly looked into. 

There was a retrospective analysis, from January 2016 to December 2020, including 2,360,860 patients; 7,855 (0.77%) with ID (amyloidosis 990, sarcoidosis 5,260 and hemochromatosis 1,625).

Read also: TAVR in Low Risk Patients: 10 Year Evolution.

Primary end point was the post-PCI combination of inhospital death, stroke and major bleeding. 

Patients with amyloidosis were older and had more comorbidities vs. sarcoidosis and hemochromatosis patients. 

Primary end point resulted more frequent in amyloidosis patients (1.6% vs. 1.1% vs. 1.18%, OR 1.6; CI del 95%, 1.1-2.44; P= .02 for amyloidosis, sarcoidosis and hemochromatosis, respectively); they also showed higher mortality (1.9% vs. 1.09% vs. 0.72%, P<0.05), and stroke (4% vs. 0% vs. 2.28%, P<0.05), but there were no significant differences in major bleeding (2.2% vs. 0.96% vs. 1.03%, p>0.05).

Read also: Sub-Analysis of the REVIVED-BCIS2: Myocardial Viability Changes Prognosis in Ischemic Cardiomyopathy Revascularization?

The cost of hospitalization and hospital stay was higher in patients with amyloidosis. 

Conclusion

Amyloidosis was associated with worse evolution after PCI, including higher inhospital mortality, intra and post procedural stroke, and socioeconomic cost. We highlight the need for a multidisciplinary approach for better assessment and further research, to better guide the screening and management strategy of these patients. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Clinical Outcomes of Percutaneous Coronary Intervention in Amyloidosis, Sarcoidosis, and Hemochromatosis.

Reference: Bilal Hussain, et al. JSCAIhttps://doi.org/10.1016/j.jscai.2023.101267. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....